title: Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy, and H2-receptor antagonists. A prospective study.
abstract: Twenty-two patients with Zollinger-Ellison syndrome were managed by a combined medical and surgical approach. Patients were treated initially with cimetidine or ranitidine. A laparotomy was performed to remove easily resectable tumors and to carry out a proximal gastric vagotomy. Tumors were found in 9 patients (41%) and all visible tumors were removed from 6 of the 9 patients. Fasting serum gastrin concentrations and serum gastrin responses to intravenous secretin were normal 6 wk after surgery in each of the patients from whom all visible tumors were resected and are normal in 4 patients, 6 wk to 5 yr after surgery. Acid secretion was reduced after vagotomy in each patient, even when tumors were not found or completely resected. Thus, vagotomy decreased the acid secretory response to endogenous hypergastrinemia. In addition, vagotomy augmented the inhibitory effect of H2-receptor antagonists on acid secretion. Follow-up has ranged from 6 wk to 6 yr (median, 2 yr). Dosages of cimetidine or ranitidine have been reduced, compared with preoperative amounts, in all but 1 patient. Two patients are taking no antisecretory drugs. Only 3 patients have had occasional symptoms of ulcer disease. Complications such as bleeding, perforation, or obstruction have not occurred in any patient. Endoscopy was performed in all patients to estimate the point prevalence of active ulcers and an ulcer was found in 1 patient. Based on these results, it is our opinion that this combined medical and surgical approach is an effective treatment for patients with Zollinger-Ellison syndrome.
authors.forename: C T
authors.initials: CT
authors.lastname: Richardson
authors.forename: M N
authors.initials: MN
authors.lastname: Peters
authors.forename: M
authors.initials: M
authors.lastname: Feldman
authors.forename: R N
authors.initials: RN
authors.lastname: McClelland
authors.forename: J H
authors.initials: JH
authors.lastname: Walsh
authors.forename: K A
authors.initials: KA
authors.lastname: Cooper
authors.forename: G
authors.initials: G
authors.lastname: Willeford
authors.forename: R M
authors.initials: RM
authors.lastname: Dickerman
authors.forename: J S
authors.initials: JS
authors.lastname: Fordtran
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002927:Cimetidine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004724:Endoscopy; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005755:Gastrins / Q000097:blood; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007813:Laparotomy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011899:Ranitidine / Q000627:therapeutic use; D014628:Vagotomy; D014629:Vagotomy, Proximal Gastric; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
chemical_list: D005755:Gastrins; D006635:Histamine H2 Antagonists; D002927:Cimetidine; D011899:Ranitidine